RAAV2-CB-hAAT Gene Vector ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 231 | Alpha-1-antitrypsin deficiency | 1 |
231. Alpha-1-antitrypsin deficiency
Clinical trials : 93 / Drugs : 77 - (DrugBank : 8) / Drug target genes : 10 - Drug target pathways : 36
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00377416 (ClinicalTrials.gov) | March 2004 | 14/9/2006 | Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency | Preclinical & Phase I/II Trials of AAV-AAT Vectors: Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV2-CB-hAAT) Gene Vector to AAT-Deficient Adults | Alpha 1-Antitrypsin Deficiency | Genetic: rAAV2-CB-hAAT Gene Vector | University of Massachusetts, Worcester | National Heart, Lung, and Blood Institute (NHLBI);Alpha-1 Foundation;University of Florida;National Center for Research Resources (NCRR) | Completed | 18 Years | N/A | All | 12 | Early Phase 1 | United States |